Commentary on “Abiraterone in metastatic prostate cancer without previous chemotherapy.” Ryan CJ, Smith MR, de Bono JS, Molina A, Logothetis CJ, de Souza P, Fizazi K, Mainwaring P, Piulats JM, Ng S, Carles J, Mulders PF, Basch E, Small EJ, Saad F, Schrijvers D, Van Poppel H, Mukherjee SD, Suttmann H, Gerritsen WR, Flaig TW, George DJ, Yu EY, Efstathiou E, Pantuck A, Winquist E, Higano CS, Taplin ME, Park Y, Kheoh T, Griffin T, Scher HI, Rathkopf DE; COU-AA-302 Investigators, Genitourinary Medical Oncology Program, Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, CA.: N Engl J Med 2013;368(2):138–48 [Epub 2012 Dec 10]; N Engl J Med 2013;368(6):584

Autor: Trump, Donald L.

Publikováno v: In Urologic Oncology: Seminars and Original Investigations November 2013 31(8):1846-1846

Commentary on 'Abiraterone in metastatic prostate cancer without previous chemotherapy.' Ryan CJ, Smith MR, de Bono JS, Molina A, Logothetis CJ, de Souza P, Fizazi K, Mainwaring P, Piulats JM, Ng S, Carles J, Mulders PF, Basch E, Small EJ, Saad F, Schrijvers D, Van Poppel H, Mukherjee SD, Suttmann H, Gerritsen WR, Flaig TW, George DJ, Yu EY, Efstathiou E, Pantuck A, Winquist E, Higano CS, Taplin ME, Park Y, Kheoh T, Griffin T, Scher HI, Rathkopf DE; COU-AA-302 Investigators, Genitourinary Medical Oncology Program, Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, CA

Autor: Donald L. Trump

Publikováno v: Urologic Oncology: Seminars and Original Investigations. 31:1846

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::843f4bac3b442643e5c048e963c83289
https://doi.org/10.1016/j.urolonc.2013.08.012

A prognostic index model for predicting overall survival in patients with metastatic castration-resistant prostate cancer treated with abiraterone acetate after docetaxel

Autor: Chi, K.N. ^*, Kheoh, T., Ryan, C.J., Molina, A., Bellmunt, J., Vogelzang, N.J., Rathkopf, D.E., Fizazi, K., Kantoff, P.W., Li, J., Azad, A.A., Eigl, B.J., Heng, D.Y.C., Joshua, A.M., de Bono, J.S., Scher, H.I.

Publikováno v: In Annals of Oncology March 2016 27(3):454-460

Adeno-to-squamous transition drives resistance to KRAS inhibition in LKB1 mutant lung cancer.

Autor: Tong X; State Key Laboratory of Cell Biology, Shanghai Institute of Biochemistry and Cell Biology, Center for Excellence in Molecular Cell Science, Chinese Academy of Sciences, Shanghai 200031, China., Patel AS; Laura and Isaac Perlmutter Cancer Center, New York University Langone Health, New York, NY 10016, USA., Kim E; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA; Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA 02115, USA., Li H; MOE Key Laboratory of Bioinformatics, Bioinformatics Division and Center for Synthetic and Systems Biology, BNRist, Department of Automation, Tsinghua University, Beijing 100084, China., Chen Y; State Key Laboratory of Cell Biology, Shanghai Institute of Biochemistry and Cell Biology, Center for Excellence in Molecular Cell Science, Chinese Academy of Sciences, Shanghai 200031, China; University of Chinese Academy of Sciences, Beijing 100049, China., Li S; Laura and Isaac Perlmutter Cancer Center, New York University Langone Health, New York, NY 10016, USA., Liu S; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA; Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA 02115, USA., Dilly J; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA; Biological and biomedical sciences program, Harvard Medical School, Boston, MA 02115, USA., Kapner KS; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA., Zhang N; Department of Respiratory and Critical Care Medicine, The Fourth Affiliated Hospital, Zhejiang University School of Medicine, Yiwu 322000, China., Xue Y; State Key Laboratory of Cell Biology, Shanghai Institute of Biochemistry and Cell Biology, Center for Excellence in Molecular Cell Science, Chinese Academy of Sciences, Shanghai 200031, China; School of Life Science, Hangzhou Institute for Advanced Study, University of Chinese Academy of Sciences, Hangzhou 310024, China., Hover L; Monoceros Biosystems, LLC, San Diego, CA 92129, USA., Mukhopadhyay S; Laura and Isaac Perlmutter Cancer Center, New York University Langone Health, New York, NY 10016, USA., Sherman F; Laura and Isaac Perlmutter Cancer Center, New York University Langone Health, New York, NY 10016, USA., Myndzar K; Laura and Isaac Perlmutter Cancer Center, New York University Langone Health, New York, NY 10016, USA., Sahu P; Laura and Isaac Perlmutter Cancer Center, New York University Langone Health, New York, NY 10016, USA., Gao Y; State Key Laboratory of Oncology in South China, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Sun Yat-sen University Cancer Center, Guangzhou 510060, China., Li F; Department of Pathology, School of Basic Medical Sciences, Fudan University, Shanghai 200032, China., Li F; Shanghai Key Laboratory of Metabolic Remodeling and Health, Institute of Metabolism and Integrative Biology, Fudan University, Shanghai 200438, China., Fang Z; Zhejiang University-University of Edinburgh Institute, Zhejiang University School of Medicine, Haining 314400, China; The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310000, China., Jin Y; State Key Laboratory of Cell Biology, Shanghai Institute of Biochemistry and Cell Biology, Center for Excellence in Molecular Cell Science, Chinese Academy of Sciences, Shanghai 200031, China., Gao J; Institute for TCM-X, MOE Key Laboratory of Bioinformatics, Bioinformatics Division and Center for Synthetic and Systems Biology, BNRist, Tsinghua University, Beijing 100084, China., Shi M; Institute of Medical Innovation, Peking University Third Hospital, Beijing 100191, China., Sinha S; Department of Biochemistry, State University of New York at Buffalo, Jacobs School of Medicine and Biomedical Sciences, Buffalo, NY 14203, USA., Chen L; State Key Laboratory of Cell Biology, Shanghai Institute of Biochemistry and Cell Biology, Center for Excellence in Molecular Cell Science, Chinese Academy of Sciences, Shanghai 200031, China; School of Life Science and Technology, Shanghai Tech University, Shanghai 200120, China; Key Laboratory of Systems Biology, Hangzhou Institute for Advanced Study, University of Chinese Academy of Sciences, Chinese Academy of Sciences, Hangzhou 310024, China; West China Biomedical Big Data Center, Med-X Center for Informatics, West China Hospital, Sichuan University, Chengdu 610041, China., Chen Y; State Key Laboratory of Common Mechanism Research for Major Diseases, Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences and School of Basic Medicine, Peking Union Medical College, Beijing 100005, China., Kheoh T; Mirati Therapeutics, San Diego, CA 92121, USA., Yang W; Mirati Therapeutics, San Diego, CA 92121, USA., Yanai I; Laura and Isaac Perlmutter Cancer Center, New York University Langone Health, New York, NY 10016, USA; Institute of Systems Genetics, New York University Langone Health, New York, NY 10016, USA., Moreira AL; Laura and Isaac Perlmutter Cancer Center, New York University Langone Health, New York, NY 10016, USA., Velcheti V; Laura and Isaac Perlmutter Cancer Center, New York University Langone Health, New York, NY 10016, USA., Neel BG; Laura and Isaac Perlmutter Cancer Center, New York University Langone Health, New York, NY 10016, USA., Hu L; State Key Laboratory of Cell Biology, Shanghai Institute of Biochemistry and Cell Biology, Center for Excellence in Molecular Cell Science, Chinese Academy of Sciences, Shanghai 200031, China., Christensen JG; Mirati Therapeutics, San Diego, CA 92121, USA., Olson P; Mirati Therapeutics, San Diego, CA 92121, USA., Gao D; State Key Laboratory of Cell Biology, Shanghai Institute of Biochemistry and Cell Biology, Center for Excellence in Molecular Cell Science, Chinese Academy of Sciences, Shanghai 200031, China., Zhang MQ; Department of Biological Sciences, Center for Systems Biology, The University of Texas, Richardson, TX 75080, USA. Electronic address: michael.zhang@utdallas.edu., Aguirre AJ; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA; Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA 02115, USA. Electronic address: andrew_aguirre@dfci.harvard.edu., Wong KK; Laura and Isaac Perlmutter Cancer Center, New York University Langone Health, New York, NY 10016, USA. Electronic address: kwok-kin.wong@nyulangone.org., Ji H; State Key Laboratory of Cell Biology, Shanghai Institute of Biochemistry and Cell Biology, Center for Excellence in Molecular Cell Science, Chinese Academy of Sciences, Shanghai 200031, China; University of Chinese Academy of Sciences, Beijing 100049, China; School of Life Science, Hangzhou Institute for Advanced Study, University of Chinese Academy of Sciences, Hangzhou 310024, China; School of Life Science and Technology, Shanghai Tech University, Shanghai 200120, China. Electronic address: hbji@sibcb.ac.cn.

Publikováno v: Cancer cell [Cancer Cell] 2024 Mar 11; Vol. 42 (3), pp. 413-428.e7. Date of Electronic Publication: 2024 Feb 22.

Early Changes in Circulating Cell-Free KRAS G12C Predict Response to Adagrasib in KRAS Mutant Non-Small Cell Lung Cancer Patients.

Autor: Paweletz CP; Belfer Center of Applied Cancer Science, Dana-Farber Cancer Institute, Boston, Massachusetts., Heavey GA; Belfer Center of Applied Cancer Science, Dana-Farber Cancer Institute, Boston, Massachusetts., Kuang Y; Belfer Center of Applied Cancer Science, Dana-Farber Cancer Institute, Boston, Massachusetts., Durlacher E; Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts., Kheoh T; Mirati Therapeutics, San Diego, California., Chao RC; Mirati Therapeutics, San Diego, California., Spira AI; Virginia Cancer Specialists Research Institute, Fairfax, Virginia., Leventakos K; Department of Oncology, Mayo Clinic, Rochester, Minnesota., Johnson ML; Sarah Cannon Research Institute Tennessee Oncology, Nashville, Tennessee., Ou SI; Chao Family Comprehensive Cancer Center, University of California-Irvine, Orange, California., Riely GJ; Department of Medicine, Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College, New York, New York., Anderes K; Mirati Therapeutics, San Diego, California., Yang W; Mirati Therapeutics, San Diego, California., Christensen JG; Mirati Therapeutics, San Diego, California., Jänne PA; Belfer Center of Applied Cancer Science, Dana-Farber Cancer Institute, Boston, Massachusetts.; Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.

Publikováno v: Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2023 Aug 15; Vol. 29 (16), pp. 3074-3080.